Temozolomide Uses, Dosage, Side Effects and Interactions
Temodar
Temodar was the first temozolomide product the FDA approved, in August 1999. The FDA rates no generic as a substitute for it.
Temozolomide is a chemotherapy drug used to treat certain aggressive brain tumors, including newly diagnosed glioblastoma and anaplastic astrocytoma, in adults.
Quick links
Ask Anything About TemozolomideType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Temozolomide in Short
- Drug class Alkylating Drug How the FDA classifies it
What it treatsTemozolomide treats two types of aggressive brain tumors in adults. It is used for newly diagnosed glioblastoma (a fast-growing brain tumor), given alongside radiation therapy and then continued as maintenance treatment. It is also used for anaplastic astrocytoma (another malignant brain tumor).
- How you get it Prescription only
- Comes asCapsule and injectionAvailable strengths
Capsule (by mouth)
- 5 mg
- 20 mg
- 100 mg
- 140 mg
- 180 mg
- 250 mg
See forms and strengths+ 1 more strengthShow fewer strengths
Injection (into a vein)
- 2.5 mg/mL
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Temodar (capsule); Temozolomide (capsule)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- Supplements and herbs25 interact 1 major, 14 moderate and 10 minor
- What pharmacies pay
- Generic$0.88 to $20.53 a capsule
- Most generic capsule strengths about $4.07
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Temozolomide (Temodar) is a chemotherapy for aggressive brain tumors in adults, mainly glioblastoma and anaplastic astrocytoma, that damages the DNA inside cancer cells so they die; on the market since about 1999, with FDA-approved generics listed, it is the standard partner to radiation for newly diagnosed glioblastoma. It is fairly well tolerated for a chemotherapy, and nausea, tiredness, constipation and hair loss are the usual complaints. Its boxed warning covers dose mix-ups across its several capsule strengths, so check the strength and number of capsules in each package before every cycle. Expect regular blood tests, because it can seriously lower blood counts and, less often, damage the liver.
Key Takeaways From the HelloPharmacist Team
- Expect a daily dose throughout radiation, then a dose on days 1 to 5 of each 28-day cycle during maintenance.
- Swallow capsules whole with water on an empty stomach; never open or chew them, and wash off any powder that touches skin.
- Call your care team right away for fever, chills, unusual bruising or bleeding, or new shortness of breath, especially if you take steroids.
- Use effective birth control during treatment and for 6 months after for women, or condoms for 3 months after for men.
Patient Information Guide for Temozolomide
What It’s Used For
Temozolomide is a chemotherapy drug approved for the treatment of certain malignant brain tumors in adults. The specific indications depend on the product and formulation:
- Newly diagnosed glioblastoma — both Temodar (capsule and injection) and Temozolomide Capsules, USP are indicated for adults, given alongside focal radiation therapy and then continued as maintenance treatment
- Adjuvant treatment of newly diagnosed anaplastic astrocytoma — Temodar (capsule and injection) is indicated for adults, beginning after completion of radiotherapy
- Refractory anaplastic astrocytoma — Temodar (capsule and injection) is indicated for adults with this condition; Temozolomide Capsules, USP are specifically indicated for adults whose disease has progressed on a regimen containing nitrosourea and procarbazine
How It Works
Temozolomide is not active in its original form. Once it enters the body, it spontaneously converts — without needing liver enzymes — into a reactive compound that directly attacks DNA in cancer cells. This process (called DNA alkylation) damages the genetic material at specific sites, causes DNA strands to break, and triggers cancer cells to undergo programmed cell death. Normal liver enzymes play only a minor supporting role.
Drug Class
Drug Class
- Alkylating Drug
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Alkylating Drug
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Alkylating Activity
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Temozolomide in the FDA’s index.
From our Patient Information GuideTemozolomide is not active in its original form. Once it enters the body, it spontaneously converts — without needing liver enzymes — into a reactive compound that directly attacks DNA in cancer cells. Read How Temozolomide Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Temozolomide in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Other alkylating agents
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Temozolomide is taken once daily, either as a capsule by mouth or as an intravenous infusion over 90 minutes, depending on the product and treatment phase. Treatment generally follows one of two phases: a concomitant phase (given every day alongside radiation for several consecutive weeks) and a maintenance or adjuvant phase (given only on the first 5 days of a repeating 28-day cycle).
- Capsules should be swallowed whole with a full glass of water; high-fat meals can reduce and delay absorption, so consistent timing relative to food matters
- Blood counts must be checked regularly before and during treatment — your doctor may pause or adjust treatment based on those results
- Always follow your prescriber's specific schedule and never adjust doses on your own
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Temozolomide Taken by Mouth
Newly diagnosed glioblastoma (a brain tumor)
Adults · Concomitant phase with radiotherapy Usual dose 75 mg/m2 once a day
- 75 mg/m2 orally once daily for 42 to 49 days
Good to know
Provide PCP prophylaxis during this phase
PCP stands for pneumocystis pneumonia.
Adults · Maintenance, Cycle 1 Starting dose 150 mg/m2 once a day
- 150 mg/m2 per day on days 1 to 5 of each 28-day cycle, beginning 4 weeks after concomitant phase completion
Adults · Maintenance, Cycles 2 to 6 Usual dose 200 mg/m2 once a day
- May increase to 200 mg/m2 per day on days 1 to 5 before starting Cycle 2 if no dosage interruptions or discontinuations are required
Good to know
If not escalated at the onset of Cycle 2, do not increase for Cycles 3 to 6
Anaplastic astrocytoma (a brain tumor)
Adults with newly diagnosed disease, after radiotherapy · Cycle 1 Starting dose 150 mg/m2 once a day
- 150 mg/m2 per day orally in a single dose on days 1 to 5 of a 28-day cycle for 12 cycles, beginning 4 weeks after the end of radiotherapy
Adults with newly diagnosed disease, after radiotherapy · Cycles 2 to 12 Usual dose 200 mg/m2 once a day
- 200 mg/m2 per day on days 1 to 5 if patient experienced no or minimal toxicity in Cycle 1
Good to know
If not escalated at the onset of Cycle 2, do not increase during Cycles 3 to 6
Adults whose disease did not respond to other treatment Starting dose 150 mg/m2 once a day Usual dose 200 mg/m2 once a day
Step by step
- Initial dose 150 mg/m2 once daily on Days 1 to 5 of each 28-day cycle
- Increase to 200 mg/m2 per day if ANC is greater than or equal to 1.5 × 10^9/L and platelet count is greater than or equal to 100 × 10^9/L at the nadir and on Day 1 of the next cycle
Good to know
Reduce next cycle by 50 mg/m2 per day if ANC is less than 1 × 10^9/L or platelets less than 50 × 10^9/L
ANC stands for absolute neutrophil count.
Temozolomide Injection
Newly diagnosed glioblastoma (a brain tumor)
Adults · Concomitant phase with radiotherapy Usual dose 75 mg/m2 once a day
- 75 mg/m2 intravenously once daily for 42 to 49 days
Good to know
Provide PCP prophylaxis during this phase
PCP stands for pneumocystis pneumonia.
Adults · Maintenance, Cycle 1 Starting dose 150 mg/m2 once a day
- 150 mg/m2 per day intravenously on days 1 to 5 of each 28-day cycle, beginning 4 weeks after concomitant phase completion
Adults · Maintenance, Cycles 2 to 6 Usual dose 200 mg/m2 once a day
- May increase to 200 mg/m2 per day on days 1 to 5 before starting Cycle 2 if no dosage interruptions or discontinuations are required
Good to know
If not escalated at the onset of Cycle 2, do not increase for Cycles 3 to 6
Side Effects
The most common side effects with temozolomide include:
Common side effects
- Hair loss (alopecia)
- Nausea and vomiting
- Fatigue
- Headache
- Constipation
- Loss of appetite (anorexia)
- Seizures (convulsions)
- Rash
- Rash and dry skin
When to get medical help
- Call your doctor right away if you develop unusual bruising, bleeding, or signs of infection (fever, chills) — these may signal dangerously low blood counts (myelosuppression)
- Seek immediate help for shortness of breath or signs of a serious lung infection such as Pneumocystis pneumonia (PCP), especially if you are on steroids
- Report yellowing of the skin or eyes, dark urine, or severe stomach pain — these can be signs of serious liver injury (hepatotoxicity)
- Tell your care team immediately if you experience new or worsening neurological symptoms — secondary cancers including leukemia have been reported with temozolomide treatment
- If a capsule is damaged and the powder contacts your skin or eyes, wash the area immediately with water and contact your care team
Serious reactions to watch for include dangerously low blood counts (which can cause infection, bleeding, or anemia), severe liver injury, a serious lung infection called Pneumocystis pneumonia, and — rarely — secondary cancers such as leukemia. Contact your care team immediately if you develop fever, unusual bleeding, yellowing of the skin or eyes, or breathing problems.
Warnings and Precautions
- Low blood counts (myelosuppression): Temozolomide can seriously suppress the bone marrow, reducing white blood cells, platelets, and red blood cells. This can lead to life-threatening infections or bleeding. Women and older adults face a higher risk. Blood counts are monitored closely throughout treatment.
- Liver damage (hepatotoxicity): Severe and fatal liver injury has been reported. Liver function tests are done at the start of treatment, throughout each cycle, and after completing treatment.
- Pneumocystis pneumonia (PCP): A serious lung infection that can develop, especially in patients receiving steroids or on longer treatment courses. Preventive treatment may be prescribed, and all patients are monitored for this.
- Secondary cancers: Cases of myelodysplastic syndrome and secondary leukemia have been observed after treatment with temozolomide-containing regimens.
- Fetal harm: Temozolomide can cause severe birth defects or pregnancy loss. Effective contraception is required during treatment and for months afterward in both women and men.
- Capsule safety: Never open, chew, or dissolve temozolomide capsules. If a capsule is damaged, avoid contact with the powder and wash any exposed area immediately.
Interactions
The number of significant drug interactions with temozolomide is relatively limited, but your care team should know about all your medications:
- Valproic acid (used for seizures or mood disorders) — may slightly decrease the clearance of temozolomide, meaning more drug stays in the body; your team will monitor you closely
- Dexamethasone, phenytoin, carbamazepine, phenobarbital, prochlorperazine, ondansetron, ranitidine, and other histamine-2 blockers — studies showed these did not meaningfully change how the body processes temozolomide, but always report every medication, supplement, and herbal product you take
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not take temozolomide if you have ever had a serious allergic reaction (including anaphylaxis) to temozolomide, dacarbazine, or any ingredient in the formulation — this is a contraindication
- Tell your doctor if you are pregnant; temozolomide can cause serious fetal harm including malformations and pregnancy loss
- Women who could become pregnant must have a pregnancy test before starting and must use effective contraception during treatment and for 6 months after the last dose
- Men with pregnant partners or partners who could become pregnant must use condoms during treatment and for 3 months after the last dose, and must not donate semen during this time; temozolomide may affect male fertility
- Do not breastfeed while taking temozolomide or for 1 week after the last dose — serious harm to a nursing infant is possible
- Older adults (especially over age 65–70) and women are at higher risk for severe low blood counts and need closer monitoring
- Safety and effectiveness have not been established in children
- If you have severe kidney impairment (creatinine clearance below 36 mL/min) or end-stage kidney disease on dialysis, the appropriate dose is not established — discuss with your doctor
- If you have severe liver impairment (Child-Pugh class C), the appropriate dose is not established — discuss with your doctor
Overdose
Taking too much temozolomide causes severe suppression of the bone marrow (myelosuppression), and at very high doses, can result in pancytopenia (dangerously low counts of all blood cell types), fever, multi-organ failure, and death. If an overdose is suspected, seek emergency medical help immediately. Treatment involves close monitoring of blood counts and supportive care.
Half-Life and How Your Body Processes It
After an oral dose, temozolomide is absorbed quickly, reaching peak blood levels in about 1 hour; a high-fat meal significantly slows and slightly reduces this absorption, so consistent dosing conditions matter. The drug has a short half-life of roughly 1.8 hours and is spontaneously converted in the body (not primarily by liver enzymes) into its active form. About 38% of a dose is recovered in the urine over 7 days, mostly as unchanged drug and breakdown products. The body handles temozolomide similarly regardless of age (19–78 years), sex, smoking status, or mild-to-moderate kidney or liver impairment; however, its behavior in patients with severe kidney or liver disease has not been well studied.
Storage
Store TEMODAR Capsules at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) . Store TEMODAR for injection refrigerated at 2°C to 8°C (36°F to 46°F).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Temozolomide
From the licensed clinical database we use, rolled up per supplement, most serious first.25 supplements and herbal products have documented interactions with Temozolomide in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 1Major
- 14Moderate
- 10Minor
- ACTIVATED CHARCOALMajor
- ACEROLAModerate
- ALPHA-LIPOIC ACIDModerate
- COENZYME Q10Moderate
- COFFEE CHARCOALModerate
- EUROPEAN MANDRAKEModerate
- GLUCOMANNANModerate
- GUAR GUMModerate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrients Temozolomide May Deplete
Nutrients Temozolomide has been linked with lower levels of, from the licensed clinical database we use.Temozolomide has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur. It means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines), not medical advice. Do not start or stop medications or supplements without professional guidance.
Temozolomide: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Temozolomide — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is temozolomide treating, and why do I need it?
How should I take the capsules — does it matter when I take them or whether I eat first?
What side effects should I expect, and which ones mean I need to call my doctor?
Why do I need so many blood tests while I'm on this medication?
Is it safe to get pregnant or father a child while on this treatment?
Can I breastfeed while taking temozolomide?
Is temozolomide available over the counter?
When was temozolomide first available?
Who makes temozolomide?
What is the brand name of temozolomide?
What is the generic name of Temodar?
What drug class is temozolomide?
Is there a generic version of temozolomide?
What strengths does temozolomide come in?
How much does temozolomide cost?
Is there a temozolomide shortage?
Where can I read the temozolomide prescribing information (package insert)?
Can you crush temozolomide?
Is temozolomide gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Temozolomide
Skip the scrolling. Ask in your own words and get an answer from Temozolomide’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Temozolomide’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Temozolomide on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Temozolomide Forms and Strengths (How It Comes)
Temozolomide comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Temozolomide inactive ingredients by manufacturer.
Capsule
How this form is used
- Temodar capsules are used for newly diagnosed glioblastoma alongside radiation and then as maintenance treatment in adults
- Temodar capsules are used for adjuvant treatment of newly diagnosed anaplastic astrocytoma and for refractory anaplastic astrocytoma in adults
- Temozolomide Capsules, USP are used for newly diagnosed glioblastoma alongside radiation and then as maintenance treatment in adults
- Temozolomide Capsules, USP are used for refractory anaplastic astrocytoma in adults whose disease progressed after nitrosourea- and procarbazine-containing treatment
- Swallow capsules whole with a full glass of water — do not open, chew, or dissolve them
- Taking Temozolomide Capsules on an empty stomach (avoiding high-fat meals) leads to more consistent absorption
- If a capsule is damaged, avoid contact with the powder — wash any exposed skin or mucous membranes immediately with water
- Follow your prescriber's exact schedule; capsules are taken once daily either every day during the radiation phase or on set days within a 28-day cycle
Injection
How this form is used
- Temodar injection is used for newly diagnosed glioblastoma alongside radiation and then as maintenance treatment in adults
- Temodar injection is used for adjuvant treatment of newly diagnosed anaplastic astrocytoma and for refractory anaplastic astrocytoma in adults
- Temodar injection is given as an intravenous infusion (into a vein) over 90 minutes
- Temodar injection is given once daily, either during the concomitant radiation phase or on specific days within a 28-day cycle, following your prescriber's schedule
Temozolomide on the U.S. Market: Products, Makers and Brands
How Temozolomide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
12 companies list 73 Temozolomide product records with the FDA, mostly as capsule, injection; the earliest marketing or approval year on record is 1999. The one brand name in the directory today is Temodar; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (12) · Unfinished injection, powder, lyophilized, for solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Temozolomide Is Used (Medicaid Data)
How many Temozolomide prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Temozolomide prescribed? Of the 1,682 medications we measure, Temozolomide ranks #1,078 by Medicaid prescriptions — more than 36% of them.
Utilization by Temozolomide product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
temozolomide 100 MG Oral Capsule Most dispensed
9 of 49 listed NDCs had Medicaid claims. RxNorm 317160
temozolomide 140 MG Oral Capsule
8 of 54 listed NDCs had Medicaid claims. RxNorm 700883
temozolomide 250 MG Oral Capsule
4 of 35 listed NDCs had Medicaid claims. RxNorm 313210
temozolomide 5 MG Oral Capsule
7 of 55 listed NDCs had Medicaid claims. RxNorm 313211
temozolomide 20 MG Oral Capsule
11 of 57 listed NDCs had Medicaid claims. RxNorm 313209
temozolomide 180 MG Oral Capsule
7 of 53 listed NDCs had Medicaid claims. RxNorm 700885
temozolomide 100 MG Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 835945
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 47 of the 304 listed Temozolomide NDCs had Medicaid claims.
Compare Temozolomide Products
A representative set of FDA-listed product records for Temozolomide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 5 mg | Oral | Accord Healthcare Inc. | ANDA | View NDC → |
| 20 mg | Oral | Accord Healthcare Inc. | ANDA | View NDC → |
| 100 mg | Oral | Accord Healthcare Inc. | ANDA | View NDC → |
| 140 mg | Oral | Accord Healthcare Inc. | ANDA | View NDC → |
| 180 mg | Oral | Accord Healthcare Inc. | ANDA | View NDC → |
| 250 mg | Oral | Accord Healthcare Inc. | ANDA | View NDC → |
| 5 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 20 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 100 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 140 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 180 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 250 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 5 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 20 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 100 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 140 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 180 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 250 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 5 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 20 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 100 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 140 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 180 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 250 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 5 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 140 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 180 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 250 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 5 mg | Oral | CivicaScript LLC | ANDA | View NDC → |
| 20 mg | Oral | CivicaScript LLC | ANDA | View NDC → |
| 100 mg | Oral | CivicaScript LLC | ANDA | View NDC → |
| 140 mg | Oral | CivicaScript LLC | ANDA | View NDC → |
| 180 mg | Oral | CivicaScript LLC | ANDA | View NDC → |
| 250 mg | Oral | CivicaScript LLC | ANDA | View NDC → |
| 5 mg | Oral | Devatis, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Devatis, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Devatis, Inc. | ANDA | View NDC → |
| 140 mg | Oral | Devatis, Inc. | ANDA | View NDC → |
| 180 mg | Oral | Devatis, Inc. | ANDA | View NDC → |
| 250 mg | Oral | Devatis, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 20 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 100 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 140 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 180 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 250 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 5 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 140 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 180 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 250 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 5 mg | Oral | OPKO Pharmaceuticals, LLC | ANDA | View NDC → |
| 20 mg | Oral | OPKO Pharmaceuticals, LLC | ANDA | View NDC → |
| 100 mg | Oral | OPKO Pharmaceuticals, LLC | ANDA | View NDC → |
| 140 mg | Oral | OPKO Pharmaceuticals, LLC | ANDA | View NDC → |
| 180 mg | Oral | OPKO Pharmaceuticals, LLC | ANDA | View NDC → |
| 250 mg | Oral | OPKO Pharmaceuticals, LLC | ANDA | View NDC → |
| 5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 140 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 180 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 250 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 140 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 180 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 250 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 💊Injection | ||||
| 2.5 mg/mL | Intravenous | Merck Sharp & Dohme LLC | NDA | View NDC → |
Showing 73 of 73 products — FDA National Drug Code Directory. See every product, package size and price: browse all 73 Temozolomide NDCs →
Temozolomide Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Temozolomide — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Temozolomide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Temozolomide FDA Approval History
How Temozolomide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Temozolomide Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list one Temozolomide recall since July 2021. It is still ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401, Country of origin: Taiwan, NDC 16571-816-51. Lots: Lot #: 1TM0524003A, Exp. Date 09/2026. FDA record D-0384-2026 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Temozolomide in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 2
- Strengths
- 7
- Forms in current FDA listings
- 2 of 2
RxCUI 37776 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1724292Its strength (SCD)-
100 mg
RxCUI 835945
-
100 mg
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Temozolomide Supply and Shortage Status
Whether Temozolomide is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Temozolomide Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Temozolomide: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.
How the Pharmacy Price Has Changed
Pick a strength to see how its price has changed since Apr 2024.
For the generic 20 mg capsule, pharmacies paid an average of $0.880 per capsule as of Nov 18, 2026, down 79% from $4.11 a year earlier.
- What pharmacies pay now
- $0.880
- per capsule, as of Nov 18, 2026
- Last 4 weeks
- No change
- from $0.880 on Oct 21, 2026
- Last 12 months
- Down 79%
- from $4.11 on Nov 19, 2025
- Lowest and highest since Apr 2024
- $0.880 to $4.81
- per capsule
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Nov 2026 | $0.880 |
| Oct 2026 | $0.880 |
| Sep 2026 | $0.880 |
| Aug 2026 | $0.880 |
| Jul 2026 | $0.880 |
| Jun 2026 | $1.15 |
| May 2026 | $1.43 |
| Apr 2026 | $1.84 |
| Mar 2026 | $1.90 |
| Feb 2026 | $2.11 |
| Jan 2026 | $4.11 |
| Dec 2025 | $4.11 |
| Nov 2025 | $4.11 |
| Oct 2025 | $4.11 |
| Sep 2025 | $4.11 |
| Aug 2025 | $4.11 |
| Jul 2025 | $4.11 |
| Jun 2025 | $4.11 |
| May 2025 | $4.11 |
| Apr 2025 | $4.11 |
| Mar 2025 | $4.11 |
| Feb 2025 | $4.11 |
| Jan 2025 | $4.81 |
| Dec 2024 | $4.81 |
| Nov 2024 | $4.81 |
| Oct 2024 | $4.81 |
| Sep 2024 | $4.81 |
| Aug 2024 | $4.81 |
| Jul 2024 | $4.81 |
| Jun 2024 | $4.81 |
| May 2024 | $4.81 |
| Apr 2024 | $4.81 |
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Capsule · Oral | 20 mg | Generic | $0.880 per capsule | NDC details & price history |
| Capsule · Oral | 100 mg | Generic | $4.07 per capsule | NDC details & price history |
| Capsule · Oral | 250 mg | Generic | $20.53 per capsule | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Temozolomide Brand Names
Temozolomide has one brand name on record: Temodar. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Temozolomide: Manufacturers and Labelers
12 companies list Temozolomide products with the FDA. By number of product records, the largest are Merck Sharp & Dohme LLC, Accord Healthcare Inc., Amneal Pharmaceuticals LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Temozolomide Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Merck Sharp & Dohme LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →